Continuous Brain-derived Neurotrophic Factor (BDNF) Infusion After Methylprednisolone Treatment in Severe Spinal Cord Injury.
10.3346/jkms.2004.19.1.113
- Author:
Daniel H KIM
1
;
Tae Ahn JAHNG
Author Information
1. Department of Neurosurgery, Stanford University School of Medicine.
- Publication Type:Original Article
- Keywords:
Regeneration;
Brain-Derived Neurotrophic Factor;
Methylprednisolone;
Spinal Cord Injuries
- MeSH:
Animals;
Anti-Inflammatory Agents/pharmacology;
Axons/pathology;
Brain-Derived Neurotrophic Factor/metabolism/*pharmacology;
Choline O-Acetyltransferase/metabolism;
Female;
GAP-43 Protein/metabolism;
Gene Expression Regulation;
Immunohistochemistry;
Methylprednisolone/metabolism/*pharmacology;
Osmosis;
Rats;
Rats, Sprague-Dawley;
Reverse Transcriptase Polymerase Chain Reaction;
Spinal Cord/pathology;
Spinal Cord Injuries/*pathology;
Time Factors
- From:Journal of Korean Medical Science
2004;19(1):113-122
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although methylprednisolone (MP) is the standard of care in acute spinal cord injury (SCI), its functional outcome varies in clinical situation. Recent report demonstrated that MP depresses the expression of growth-promoting neurotrophic factors after acute SCI. The present study was designed to investigate whether continuous infusion of brain-derived neurotrophic factor (BDNF) after MP treatment promotes functional recovery in severe SCI. Contusion injury was produced at the T10 vertebral level of the spinal cord in adult rats. The rats received MP intravenously immediately after the injury and BDNF was infused intrathecally using an osmotic mini-pump for six weeks. Immunohistochemical methods were used to detect ED-1, Growth associated protein-43 (GAP-43), neurofilament (NF), and choline acethyl transferase (ChAT) levels. BDNF did not alter the effect of MP on hematogenous inflammatory cellular infiltration. MP treatment with BDNF infusion resulted in greater axonal survival and regeneration compared to MP treatment alone, as indicated by increases in NF and GAP-43 gene expression. Adjunctive BDNF infusion resulted in better locomotor test scores using the Basso-Beattie-Bresnahan (BBB) test. This study demonstrated that continuous infusion of BDNF after initial MP treatment improved functional recovery after severe spinal cord injury without dampening the acute effect of MP.
